Posted inBiotechnology
Neuropsychiatric Traits Link to Parkinson’s Risk
In a groundbreaking study published in npj Parkinson’s Disease, researchers have unveiled compelling new insights into the intricate relationship between…
Posted inBiotechnology
KIAA1429 Boosts FAM84B mRNA, Fueling Colorectal Cancer
In a groundbreaking study published in Biochem Genet, researchers have unveiled critical insights into the molecular mechanisms that underpin colorectal…
Posted inBiotechnology
Emerging Biochemical Markers Enhance Ovarian Cancer Diagnosis
In a groundbreaking study that could revolutionize the way ovarian carcinoma is diagnosed and monitored, researchers have identified four novel…
Posted inGenetics
Rentschler Biopharma and Coriolis Pharma Collaborate on Integrated Biopharma Solutions
CDMO Rentschler Biopharma and Coriolis Pharma, a CRDO, say they agreed to offer clients end-to-end solutions from early formulation through…
Posted inGenetics
World HUPO 2025: Proteomics Beyond Mass Spec to Ecosystem Impact
World HUPO 2025 When HUPO picked Toronto for its 24th World Congress, I imagined crisp fall air by the lake…
Posted inBiotechnology
CDER head Richard Pazdur set to retire shortly after appointment
Mere weeks after being named the nation’s top drug regulator, Richard Pazdur, M.D., is taking steps to retire as head…
Posted inMedical Technology
Boston Scientific claims European approval for Farapoint focal pulsed field ablation catheter
Boston Scientific has obtained an approval in Europe for the latest addition to its pulsed field ablation portfolio, with the…
Posted inBiotechnology
A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine
While the prevalence of Parkinson’s disease (PD) has doubled over the past 20 years, the treatment paradigm has remained largely…
Posted inBiotechnology
FDA issues draft guidance to reduce primate testing for certain antibodies
The FDA has released a plan to stop or reduce the use of primates for testing the safety of certain…
Posted inBiotechnology
Janux T-cell engager data sink stock, but analysts still see best-in-class potential
Almost exactly one year ago, Janux Therapeutics unveiled early data for its investigational T-cell engager that wowed investors and analysts…